Last updated: July 24, 2026
AltaThera Pharmaceuticals LLC’s case against Hyloris Pharmaceuticals SA in the U.S. District Court for the District of New Jersey (case no. 1:22-cv-04620) is a Paragraph IV-style patent infringement dispute tied to an FDA approval pathway and a proposed generic/alternative launch. The litigation posture and typical settlement mechanics in this case type indicate the likely commercial timeline hinges on (1) which Orange Book patents AltaThera lists as asserted, (2) whether Hyloris is pursuing a design-around, and (3) whether the parties resolve via a licensing/consent judgment that sets a launch date or designates an exclusivity carve-out.
This summary is limited to what can be stated without making unsupported claims about asserted patents, settlement dates, or outcomes. No reliable, case-specific docket events or patent identifiers are provided in the prompt, so only an unambiguous procedural-and-strategy analysis can be produced.
What is AltaThera Pharmaceuticals LLC v. Hyloris Pharmaceuticals SA (1:22-cv-04620) about?
Short answer: It is a U.S. patent infringement litigation filed by AltaThera against Hyloris in connection with a contested FDA approval and an abbreviated or otherwise constrained competitive entry.
Where is the case filed and what procedural posture is typical?
- Court: U.S. District Court (District of New Jersey)
- Case number: 1:22-cv-04620
- Nature of dispute (typical): patent infringement tied to FDA drug approval activity, commonly arising when a generic or alternate applicant challenges Orange Book-listed patents.
What claims are usually at issue in this case type?
In Paragraph IV-linked disputes, the asserted issues typically include:
- Non-infringement or invalidity of the asserted Orange Book patent(s)
- Infringement theories tied to the proposed product’s structure, formulation, method of manufacture, and/or method of use
- Injunctive relief and damages tied to launch timing
Which patents are asserted in AltaThera v. Hyloris (1:22-cv-04620)?
Answer: Not determinable from the information provided.
Why patent identification is required to analyze enforceability
A litigation outcome can hinge on:
- Whether the asserted patents are composition, formulation, method-of-use, or manufacturing-method
- Claim scope and how the defendant’s product maps to the elements
- Whether the patents expire earlier than any available exclusivity or settlement trigger
Without the asserted patent numbers (or at least the Orange Book entry), any listing would be speculative and would distort risk assessments for licensing, entry, and investment decisions.
What is the litigation timeline for AltaThera v. Hyloris (1:22-cv-04620)?
Answer: Not determinable from the information provided.
What timeline checkpoints typically matter
When analyzing a Hatch-Waxman-style dispute, the critical milestones are:
- Complaint filing date and the initial Rule 16 schedule
- Claim construction events (Markman)
- Summary judgment motions on infringement/invalidity
- Trial scheduling (if unresolved)
- Any settlement or consent judgment that sets a launch date
Without docket dates, a timeline cannot be reconstructed reliably.
How strong is AltaThera’s patent estate in this case?
Answer: Not determinable from the information provided.
What “strength” depends on in practice
Even without reading the full record, patent estate strength in these cases usually correlates with:
- Claim breadth versus likely design-around space
- Prior art maturity at the time of filing
- Strength of enablement and written description
- Whether the asserted patents cover the defendant’s product in a straightforward “literal infringement” way
- Whether the patents are early-life (composition/formulation) or later-life (process/secondary) with different commercial and litigation incentives
Without the asserted patent list and claim mappings, strength cannot be evaluated.
When does exclusivity end, and when could Hyloris launch if it wins AltaThera v. Hyloris?
Answer: Not determinable from the information provided.
What drives “win-to-launch” timing
Even if the defendant prevails, launch timing is shaped by:
- The patents successfully challenged or found not infringed/invalid
- Any remaining unasserted Orange Book patents
- Non-patent regulatory protections (regulatory exclusivity, if any, depending on the product)
- Practical manufacturing and labeling readiness timelines after litigation clearance
Without identifying the Orange Book patents and expiry dates, exclusivity timing cannot be computed.
What Paragraph IV risks exist for Hyloris in AltaThera v. Hyloris (1:22-cv-04620)?
Answer: Not determinable from the information provided.
Common Paragraph IV risk vectors
Where risk is elevated (fact patterns vary by product), it often comes from:
- Narrow design-around feasibility for formulation/process claims
- Correlation between commercial route and the patent’s claim scope
- Invalidation resistance due to late-breaking art or strong secondary indicia
- Procedural posture issues, including adverse claim construction outcomes
A product-specific assessment requires the asserted patents and defendant’s proposed product characteristics.
How does Hyloris’ product design-around strategy typically work in Hatch-Waxman litigation?
Answer: Not determinable from the information provided.
Typical mechanisms defendants use
In these disputes, defendants often pursue:
- Element-by-element non-infringement (changing formulation components, ratios, particle size, release profiles, or manufacturing steps)
- Invalidity by obviousness or anticipation through prior art drug products and publications
- Fewer asserted claims by narrowing the case to core patent themes, if the claimant’s complaint is vulnerable to early dismissal
Without the defendant’s design-around details, this cannot be applied to this case without conjecture.
What is the likely resolution path: trial vs settlement in AltaThera v. Hyloris (1:22-cv-04620)?
Answer: Not determinable from the information provided.
Settlement dynamics in this docket category
In patent infringement disputes tied to FDA approvals, resolutions commonly take the form of:
- A settlement that dismisses the case in exchange for a delayed launch date
- A license that permits entry on specified terms
- A consent judgment reflecting a noninfringing finding or negotiated entry window
- A “no-early-launch” agreement that keeps branded market share during peak exclusivity or while key patents remain in force
A credible call requires knowledge of any settlement motion, docket entry, or consent judgment document.
What is the Orange Book status of the relevant AltaThera product and which patents are listed?
Answer: Not determinable from the information provided.
Why Orange Book listings must be tied to the asserted patents
Orange Book listings determine:
- The patent numbers and expiration dates that define the infringement window
- Whether the defendant’s filing is genuinely challenging specific patents
- Whether other Orange Book patents remain unchallenged and could block launch even after partial victory
Without the drug name and NDA/ANDA/BLA identifier, an Orange Book mapping cannot be produced.
What FDA pathway issue matters most for this litigation?
Answer: Not determinable from the information provided.
What FDA pathway usually affects
- Generic applicants’ ability to use FDA exclusivity carve-outs
- Whether the dispute relates to a Paragraph IV certification or a different certification scheme
- Whether the claimed patent type affects the legal theory (composition versus use versus manufacturing)
No product or FDA application identifier was provided.
Commercial impact: How much revenue is at risk for AltaThera and what is Hyloris’ entry exposure?
Answer: Not determinable from the information provided.
What revenue-at-risk analysis requires
- Branded product net sales and forecast curves
- Timing to generic entry (based on patent/exclusivity clearance)
- Any authorized generics, supply agreements, or launch inhibitors
- Court-driven delay from injunction risk
No product, market, or sales data is provided.
Key Takeaways
- Case identity: AltaThera Pharmaceuticals LLC v. Hyloris Pharmaceuticals SA, D.N.J., 1:22-cv-04620.
- Core issue (category): A U.S. patent infringement dispute linked to FDA-driven market entry, consistent with Paragraph IV-style litigation patterns.
- What cannot be concluded from the provided input: asserted patent numbers, litigation milestones, claim-construction rulings, dispositive motions, settlement terms, Orange Book status, exclusivity dates, and launch timing.
- Practical next step for any high-stakes decision: litigation analysis must be anchored to the asserted Orange Book patents and the specific docket events (scheduling orders, claim construction orders, summary judgment outcomes, and settlement/consent entries).
FAQs
1) Does AltaThera v. Hyloris mean Hyloris is challenging a Paragraph IV certification?
Not determinable from the provided input.
2) What is the fastest way to estimate launch timing from this docket?
By mapping the asserted Orange Book patents to their expiration and remaining unasserted patents, then tying clearance to any settlement or court-ordered timing. Those data are not provided here.
3) What typically happens if the court narrows claim scope in Hatch-Waxman litigation?
It can shift the case toward non-infringement or reframe obviousness theories. The actual effect in this case depends on the claim construction record, which is not provided.
4) Are settlements in cases like this usually licenses or agreed launch dates?
Most commonly they use negotiated launch dates or licenses, but the specific mechanism for this docket is not provided.
5) Can remaining unasserted patents still block Hyloris entry even if some patents fall?
Yes, and this is a frequent risk vector. The presence and status of unasserted patents cannot be confirmed from the provided input.
References
No external sources were provided in the prompt, and no case docket details, court filings, Orange Book identifiers, or patent numbers were included. As a result, no APA citations can be generated without introducing unverifiable claims.
